The Changing Landscape of Treatment for EGFR+ Lung Cancer

The Changing Landscape of Treatment for EGFR+ Lung Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Significance of FLAURA in EGFR+ NSCLC

October 19th 2018

EP. 2: Osimertinib For Uncommon EGFR Mutations in NSCLC

October 19th 2018

EP. 3: Overcoming Resistance to EGFR Inhibitors in NSCLC

October 19th 2018

EP. 4: Managing Disease Progression in EGFR+ NSCLC

October 19th 2018

EP. 5: Emerging EGFR Inhibitors in NSCLC

October 19th 2018

EP. 6: Promising Treatment Combinations in EGFR+ NSCLC

October 19th 2018

EP. 7: EGFR Inhibitors as Adjuvant Therapy in NSCLC

October 19th 2018

EP. 8: Improving the Management of EGFR+ NSCLC

October 19th 2018

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2026

FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay

Five Under 5: Top Oncology Videos for the Week of 10/5/2026

FDA Grants Fast Track Designation to PSV359 for Advanced FAP-Positive Solitary Fibrous Tumors